



Date: 24<sup>th</sup> February, 2026

To The Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra – Kurla Complex Bandra (East) Mumbai – 400 051 <b>Stock Code : INDOCO</b>	To The Listing Department <b>Bombay Stock Exchange Limited</b> Floor 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Stock Code : 532612</b>
---	--

Dear Sir/Madam,

**Subject: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

We are pleased to announce the final approval of the Company’s Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution, 10 mg/mL, to market a generic equivalent to the reference listed drug (RLD), Briviact 10 mg/mL, of UCB, Inc. This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.

Please find enclosed Press Release in this regard.

This is for your information and records.

**Thanking you,  
Yours faithfully,  
For Indoco Remedies Limited**



**Ramanathan Hariharan  
Company Secretary & Head Legal**



## PRESS RELEASE

### **Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL**

**Mumbai, February 24, 2026:** Indoco Remedies Ltd. announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution, 10 mg/mL, to market, a generic equivalent to the reference listed drug (RLD), Briviact 10 mg/mL, of UCB, Inc.

Brivaracetam Oral Solution, 10 mg/mL, have been determined to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Briviact 10 mg/mL of UCB, Inc.

Brivaracetam Oral Solution, will be manufactured by Indoco Remedies Limited, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India.

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older.

Commenting on the achievement, Ms. Aditi Panandikar, Managing Director said, "The ANDA approval for Brivaracetam is a significant milestone for us as we continue to strengthen our presence in the Regulated Markets. We are committed to offering innovative and affordable healthcare to patients worldwide."

#### **About Indoco Remedies Limited:**

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The Company's turnover is US\$ 180 million with a human capital of over 6000 employees, including over 400 skilled scientists and field staff who are the strength of the organization.

The Company has 10 manufacturing facilities, 6 for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 106 million prescriptions annually from over 2,40,000 doctors belonging to various specialties. Indoco has 10 domestic marketing divisions, a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gynaecology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensiform, SensodentKF, Aloja, Glychek, Kidodent, Subital, Rexidin, MCBM 69, Methycal, Dropizin, Noxa, Homide, Cal-Aid, Ninaf, Cital-Uti, Otorex, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

#### **For Media enquiries please contact:**

**Corporate Communications | [+91 22 62871000](tel:+912262871000)**

E-mail: [corpcom@indoco.com](mailto:corpcom@indoco.com)